AI Article Synopsis
- The study aimed to assess the effectiveness of nedaplatin in patients allergic to carboplatin.
- A review of medical records was conducted for patients with specific cancers and hypersensitivity history from 2010 to 2016.
- The results showed a higher response rate (71.4%) in patients treated with nedaplatin compared to 30.0% in those treated with other drugs, indicating that nedaplatin is safe and effective for this group.
Article Abstract
Objective: To evaluate the benefits of nedaplatin treatment in patients with a history of hypersensitivity reactions to carboplatin.
Materials And Methods: We retrospectively reviewed the medical records of patients with ovarian, fallopian, and peritoneal cancers and with a history of hypersensitivity to carboplatin between January 2010 and December 2016 at the Department of Gynecology in the Saitama Medical Center associated with Jichi Medical University. We studied the response rate to treatment with a nedaplatin-based regimen compared to that of a carboplatin regimen. Fisher's exact test was used to determine statistical significance.
Results: Thirty-one patients with a past hypersensitivity to carboplatin were treated with nedaplatin-based regimen, while ten patients were treated with other drugs. The response rates in the nedaplatin- and non-nedaplatin-treated patient groups were 71.4% and 30.0%, respectively (P = 0.021). Among all the patients, only one experienced hypersensitivity reaction to nedaplatin.
Conclusion: The nedaplatin regimen following hypersensitivity to carboplatin was safe, feasible, and effective in achieving complete or partial response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tjog.2020.05.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors of Hypersensitivity Reactions to Carboplatin: A Systematic Review and Meta-analysis.
J Allergy Clin Immunol Pract
December 2024
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea. Electronic address:
Background: The development of hypersensitivity reactions (HSRs) to carboplatin can interrupt anticancer treatment and may shorten patient survival. Several studies have evaluated the risk factors for carboplatin HSRs, but the results have been inconclusive.
Objective: This systematic review and meta-analysis aim to establish a consensus on the risk factors of HSRs to carboplatin in cancer patients.
Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study).
Cancers (Basel)
November 2024
Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki 036-8563, Japan.
: The usefulness of bevacizumab (BEV) as first-line chemotherapy for advanced ovarian clear cell carcinoma (CCC) was retrospectively evaluated at Tohoku Gynecologic Cancer Unit institutions. : A total of 81 patients (52 patients without BEV and 29 with BEV) with advanced ovarian CCC who received initial platinum-based chemotherapy were enrolled. We selected 26 patients each without and with BEV according to propensity score matching methods, and compared the platinum-resistant recurrence rate, response rate, progression-free survival (PFS), overall survival (OS), and adverse events between the two groups.
View Article and Find Full Text PDFRapid Desensitization to Antitumoral Agents. Result from a Retrospective Study, DESARCh.
Hosp Pharm
September 2024
Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Article Synopsis
- Antitumoral drugs (ADs) can trigger hypersensitivity reactions (DHRs), and rapid drug desensitization (RDD) protocols are employed to safely administer these treatments at effective doses.
- The "DESARCh" retrospective study assessed the RDD protocols carried out at an Italian hospital over 11 years, including a detailed 5-step infusion method to reduce DHR incidence for patients with various cancers.
- Out of 66 RDD protocols for 25 female patients, the overall success rate was 81.82%, although carboplatin had a significantly lower success rate compared to other ADs, highlighting the need for further research in this area.
Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series.
J Dermatol
January 2025
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Article Synopsis
- Immune checkpoint inhibitors (ICIs), like pembrolizumab (PEM), are effective against tumors but can cause serious skin side effects (cutaneously adverse events or CAEs), especially when used in combination therapies.
- Severe CAEs may require stopping the immunotherapy, and the risk is higher when ICIs are used with other treatments compared to when they are used alone.
- A case study of 19 women with advanced cervical cancer highlighted the occurrence of severe CAEs, including erythema multiforme and anaphylaxis, stressing the need for tight monitoring of skin reactions during PEM combination therapy to ensure patient safety.
Concurrent sarcoidosis and metastatic lung cancer in a patient with ring-enhancing brain lesions.
BMJ Case Rep
October 2024
Department of Medicine, Duke University School of Medicine, Durham, USA.
This case discusses a male in his 40s with no prior medical history who presented to the emergency room with headaches and blurred vision and was found to have ring-enhancing lesions on brain MRI. Chest imaging revealed bilateral pulmonary nodules with a dominant right upper lobe nodule. On lung tissue sampling, he was found to have concurrent sarcoidosis and non-small cell lung cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!